Omega Inc. started a project to create a new drug on April 1, 2012. The development phase commenced on July 1, 2013 and the 'Wonder Drug' was ready for its intended use on July 1, 2014. Costs were incurred in each phase (Research- 243,350 and Development- 426,250 ). The registered patent on the drug is five years and there is no intention to renew the patent. Omega's year-end is June 30, 2015. What is the amortization of the drug for the 2015 financial year? Select the best response, and then click Submit. 85,250 35,520 55,800 29,600